Related Experiment Video
Updated: May 17, 2026

14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Continuity clinics in oncology training programs in Canada.
1The Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON.
Current Oncology (Toronto, Ont.)
|November 13, 2012
Summary
Continuity clinics (CCs) are valuable for oncology training in Canada, with most program directors and trainees finding them important. Patients, however, desire more supervision than trainees or directors anticipate.
Area of Science:
- Medical Education
- Oncology
- Clinical Practice
Background:
- Continuity clinics (CCs) offer trainees longitudinal patient follow-up and semi-autonomous practice opportunities.
- Data on the utility of CCs in Canadian oncology training programs are limited.
Purpose of the Study:
- To assess the utility of continuity clinics in Canadian oncology training programs.
- To evaluate the perspectives of program directors, trainees, and patients on CCs.
Main Methods:
- Surveys were distributed electronically to medical and radiation oncology program directors and trainees.
- Patient attitudes toward CCs were assessed via surveys at The Ottawa Hospital Cancer Centre.
- Data were collected using SurveyMonkey and analyzed to determine participation rates and opinions.
Main Results:
- 37% of trainees and 47% of program directors reported participation in CCs.
- 80% of respondents deemed CCs "important" or "very important" for training.
- Lack of clinic space was the primary challenge; patients desired more trainee supervision than anticipated.
Conclusions:
- Continuity clinics are perceived as beneficial for oncology training by program directors and trainees.
- Patient desire for increased trainee supervision in CCs is a key factor for implementation.
- Balancing trainee autonomy with adequate patient supervision is crucial in CCs.
Related Concept Videos
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

